SEC Tracker
Get the app

Vir Biotechnology VIR

SVF Endurance (Cayman) (10% Stockholder) plans to sell 1,251,303 VIR shares, about $8.1M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Nov 25, 2025
  2. Broker: BTIG, LLC
  3. Shares acquired by: Acquired upon the automatic conversion of convertible preferred stock. The convertible preferred stock was acquired and fully paid for in multiple transactions from August 2017 to January 2019.
  4. 10b5-1 plan adopted: Sep 3, 2025

All of SVF Endurance (Cayman)'s insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Vir Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
  3. Immunome IMNM public float $729M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.